Uploaded August 2026 | Updated September 2026, 3 weeks ago

---

Kailera Therapeutics raised $7.18 million in its April 2026 Nasdaq debut and reported $1.7 billion in cash and equivalents at the end of June. Its Q2 net loss reached $111 million, with $101 million in R&D spending as it advances its obesity pipeline.

Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.

#LongevityTechnologyUnlocked #LongevityPodcast #ObesityDrugs #KaileraTherapeutics #Biotech #DrugDevelopment